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Abstract: Cardiovascular (CV) disease is highly prevalent in the population with chronic kidney 
disease (CKD), where the risk of CV death in early stages far exceeds the risk of progression to 
dialysis. The presence of chronic kidney disease-mineral and bone disorder (CKD-MBD) has shown 
a strong correlation with CV events and mortality. As a non-atheromatous process, it could be 
partially explained why standard CV disease-modifying drugs do not provide such an impact on 
CV mortality in CKD as observed in the general population. We summarize the potential association 
of CV comorbidities with the older (parathyroid hormone, phosphate) and newer (FGF23, Klotho, 
sclerostin) CKD-MBD biomarkers. 
Keywords: chronic kidney disease; uremic cardiopathy; left ventricular hypertrophy; phosphate; 
PTH; FGF23; klotho; sclerostin. 
Key Contribution: Although the management of CKD patients was significantly improved, CV 
mortality continues to be at a higher rate. Here the impact of CKD-MBD has already extended 
beyond the role in the skeleton, so we tried to go from the candidate mineral disorder to 
cardiovascular abnormalities. Focusing on such toxins and/or their relevant mediators at early CKD 
stages might help to interfere on time with the vicious cycle of the cardio–renal connection and 
improve the outcome of the patients. 
 
1. Introduction 
Over the past 25 years, chronic kidney disease (CKD) has become an enormous public health 
issue with a high risk of morbidity and fatal outcome. Cardiovascular disease (CVD) is the most 
frequent (39%) cause of mortality in this population of end-stage renal disease (ESRD) [1], whereas 
the risk of CV mortality in early-stage CKD far exceeds the risk of progressing to dialysis [2]. 
Cardiovascular involvement is evident, initiates in the early stages of CKD (according to the K/DOQI 
CKD classification), being present in about 80% of prevalent hemodialysis patients [1]. CKD being 
recognized as an independent risk factor for CVD is a topic of debate on whether it should be 
recognized as a coronary disease risk equivalent, independent from the risk of diabetes and 
hypertension [1].  
The complicated relationship between CVD and kidney disease reflects the interaction of 
traditional, non-traditional cardiovascular risk factors modified by CKD, and new CKD linked risk 
factors like uremic toxins, CKD-mineral and bone disorder (MBD), anemia, hypervolemia, oxidative 
stress, inflammation, insulin resistance, etc. [3,4]. Uremic toxins with presumed cardiovascular 
toxicity including FGF23 and protein-bound uremic toxins (PBUTs) like indoxyl sulfate, p-cresyl 
sulfate, start to accumulate in the body since early-stages of CKD, and elimination no longer relies on 
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only renal replacement therapy. It is more than clear that CVD in CKD is an accelerated 
atherosclerosis. 
Out of the five subtypes of cardiorenal syndromes classified so far, primary CKD leading to an 
impairment of cardiac function, can be established in the context of cardiorenal syndrome type 4 [5]. 
The interrelation between reduced renal function and altered cardiac remodeling in patients with 
CKD is termed uremic cardiomyopathy [6].  
CKD-related cardiomyopathy has multifactorial pathophysiology. Here the effect of CKD-MBD 
has been already extended beyond the role in the skeleton. The pathogenesis of CKD-MBD has 
initially been described as a decrease in 1,25-dihydroxy vitamin D [1,25(OH)2 D3] levels leading to 
increased serum parathyroid hormone (PTH) level, following changes in calcium and phosphorus 
metabolism [7]. Vitamin D deficiency, together with secondary hyperparathyroidism (sHPTH) and 
hyperphosphatemia, was defined as the main factor influencing high cardiovascular risks in CKD 
patients [7]. The identification of new players such as FGF23, klotho [3], and sclerostin has changed 
what has been portrayed above because of their role not only in the sHPTH pathophysiology but also 
throughout their direct or indirect involvement in the uremic cardiovascular disease [7]. FGF23, 
klotho, Fetuin-A/Calciprotein particles, and sclerostin could be used among other old and relevant 
markers, as biomarkers for CV risk prediction in CKD [8]. 
We summarize here the potential association of those comorbidities with the older (parathyroid 
hormone, phosphate, Vit D deficiency) and newer (FGF23, Klotho, sclerostin) CKD-MBD biomarkers 
[2]. 
1.1. Pathophysiology of Uremic Cardiomyopathy in CKD Patients 
Uremic cardiomyopathy in patients with CKD or ESRD is a result of the volume and pressure 
overload, and the uremic state itself, including left ventricular hypertrophy (LVH), the diffuse 
interstitial fibrosis, and microvascular disease [3,5,6]. Histopathological examination of postmortem 
cardiac tissue samples in hemodialysis patients showed increased cardiomyocyte diameter, reduced 
capillary length density, and increased interstitial volume [9]. 
1.1.1. Left Ventricular Cardiomyopathy 
LV hypertrophy is the most frequent cardiac finding in dialysis patients, and it is almost 
universal [8]. The prevalence of LVH is estimated to be between 16% and 31% in individuals with 
GFR >30 mL/min; it rises to 60%–75% before renal replacement therapy initiation and increases up to 
90% after the dialysis initiation [10]. It is related to chronic volume and pressure overload, 
neurohormonal activation, and uremic toxin accumulation [11]. The pathophysiological factors 
involved in LVH of CKD patients are (1) related to afterload, (2) related to preload, and (3) not related 
to afterload or preload [5,12–14]. The ones in the first group give a picture of an increase in systemic 
arterial resistance, elevated arterial blood pressure, and reduced large-vessel compliance [11–14] 
partially correlated to aortic ‘calcification’, which is specific in CKD patients. LV hypertrophy is a 
compensatory response that acts to maintain wall stress in the course of long-term loading conditions, 
where all these factors lead to myocardial cell thickening and concentric LV remodeling. Among the 
preload-related factors, the role of intravascular volume expansion (salt and fluid retention), 
secondary anemia, and the presence of arteriovenous fistulas which result in myocardial cell 
lengthening and eccentric or asymmetric LV remodeling need to be underlined. Both afterload and 
preload-related factors act with additive and/or synergistic effects. It is suggested that fluid overload 
and increased arterial stiffness play a role in LVH even before the start of dialysis therapy [15]. 
Arteriosclerosis, being a hallmark of arterial remodeling in ESRD, is characterized by diffuse 
calcification in combination with dilatation, and an increased wall thickness of the medial layer of 
the aorta and its main branches which drives increased arterial stiffness [11,16,17]. Here, LVH 
happens regardless of the effective control of hypertension. Blood pressure independent LVH also 
occurs in diabetics with known diabetic nephropathy [18]. 
Hypertrophied hearts have reduced coronary blood flow reserve and are at increased risk for 
myocardial ischemia [19]. The coexistence of left atrial enlargement is common, and atrial fibrillation 
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occurs frequently. Eventually, continuing LV load can promote structural changes in the LV, 
apoptosis of cardiomyocytes, and triggers metabolic pathways able to increase the extracellular 
matrix production up to fibrosis [9,10,20,21].  
1.1.2. Interstitial Fibrosis 
Diffuse interstitial cardiac fibrosis is reported in uremic patients and progresses with advancing 
of CKD [11,13,20–22]. Recently, it was nicely reported that in early-stage CKD patients, noninvasive 
imaging biomarkers of myocardial fibrosis do not change if renal function remains stable [22]. 
Fibrosis alters the architecture of myocardium promoting the progression of cardiac disease 
(progressive impairment in contractility, systolic and diastolic dysfunction, dilated cardiomyopathy, 
congestive heart failure) towards heart failure (HF) and increase the risk for sustained atrial and 
ventricular arrhythmias [9]. This may explain why CKD patients are at increased risk of sudden 
cardiac death (SCD) [23]. Recent studies have pointed out that not only CKD-MBD well-known 
biomarkers like phosphate, vit D, and PTH [3,5,7] but also novel and early ones like FGF23 are 
involved in the regulation, growth, and differentiation of cardiac myocytes being players in the 
pathogenesis of LVH [3,5,11,12]. 
1.1.3. Microvascular Disease 
The coronary microvascular function is not well studied in CKD. Based on one old report around 
30% of dialysis patients with clinical angina have only moderate epicardial coronary artery disease 
(CAD) [24], possibly explained with endothelial dysfunction associated with microvascular disease 
[11,25]. The presence of structural and coronary functional changes contributes to myocardium-
capillary mismatch which is not specific to uremia [9]. Under the condition of disbalance between 
high oxygen demand and a low oxygen supply microvascular coronary disease exposes 
cardiomyocytes to the risk of hypoxemia and beyond in possible ischemic myocardial injury at the 
microvascular level, which could be an explanation for persistently elevated serum troponin levels 
found in these patients [3,26]. 
Coronary artery calcification (CAC) as measured by computed tomography is noninvasive with 
excellent accuracy measurement of the burden of coronary atherosclerosis. CKD patients have higher 
CAC scores compared with age-matched controls without CKD, and those without baseline 
calcification present higher incidence rates of developing future de novo CAC [27]. Besides 
traditional factors, here, in particular, there are nontraditional risk factors such as 
hyperphosphatemia, calcium-phosphorus product, homocysteine, osteoprotegerin, and sclerostin 
which were independently related to the presence and high CAC scores [8,27,28]. 
1.2. Role of Phosphate in Uremic Cardiomyopathy 
Phosphate toxicity is a well described phenomenon in CKD [29,30]. Less than 1% of total 
phosphate is found in the blood and its balance was regulated by the interplay of bone, the 
parathyroid glands, intestines, and kidneys. The kidney is the principal organ regulating phosphate 
homeostasis. Following the loss of glomerular filtration rate (GFR), tubular phosphate reabsorption 
is significantly decreased by dual effect of compensatory increased concentration of two important 
hormones, the parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF23). In addition, 
FGF23 suppresses the activation of vitamin D and acts to decrease parathyroid hormone synthesis 
and secretion being the major trigger in the path of CKD-MBD. FGF23 needs its cofactor klotho to 
ensure phosphate clearance [31]. Since the expression of Klotho declines in the kidney in the earlier 
stage CKD, FGF23 rises due to the resistance to FGF23 signaling in the kidney [31,32]. Although renal 
α-Klotho levels were significantly reduced and serum FGF23 levels were significantly elevated they 
can maintain serum phosphate within the normal range in early and intermediate stages of CKD. 
However, as CKD progresses, these defense mechanisms are ineffective, so phosphate retention may 
occur, and hyperphosphatemia develops. 
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Elevated serum phosphate has revealed as a non-traditional risk factor for cardiovascular events 
in CKD and partially explains the increased mortality risk in CKD [29,31,32].  
The role of phosphate in vascular calcification has been the focus of intense investigation in the 
past decades. In elevated phosphate conditions, the biology of the arterial tunica media is found 
greatly altered; there is vascular smooth muscle cell (VSMC) transition to bone phenotype, apoptosis 
inactivation of local anti-calcification factors, and elastin degradation [33,34].  
The PiT-1 phosphate transporter seems to be a key mediator in phosphate-induced VSMC, 
activating bone formation-related gene expression, osteochondrogenic differentiation, and was 
recently shown to be relevant in cell proliferation and embryonic development, referring more 
functions for this protein than previously thought [33–35]. Vascular mineralization, especially 
affecting the coronary artery, is strongly related to mortality of CKD patients independently from the 
established atherogenic markers. The rate of coronary artery mineralization in CKD patients 
undergoing hemodialysis treatment was reported to be five times higher than in the non-dialysis 
CKD patients and is associated with features of valvular calcifications sharing the same changes 
[16,31,36]. Moreover, valvular heart disease is one of the most common complications observed in 
patients with CKD [37,38] and hyperphosphatemia directly affects progression of valvular 
calcification. 
The progression of valvular calcification leads to obstruction of left ventricular outflow and 
inflow from the left atrium to the left ventricle associated with hemodynamic changes resulting in 
very difficult clinical conditions [39]. 
Endothelial dysfunction is another early and crucial step in the development of cardiovascular 
disease apart from vascular calcification. Fewer reports have shown that phosphate level not in the 
physiologic range directly affects endothelial function and vascular remodeling [40,41]. Elevated 
phosphate level impairs endothelial function, hence diminishing microvascular function, angiogenic 
ability, and promoting endothelial stiffness [42]. 
Endothelial stiffness reflects changes in the structural and functional properties of the 
endothelium. These include cytoskeleton restructuring, successive mechano-signaling activity, 
intensified endothelial turnover (apoptosis), and diminished NO bioavailability [42]. 
High serum phosphate levels in HD patients were found to be independently associated with 
an increased number of endothelial microparticles (EMPs) and circulating (detached) endothelial 
cells [43]. These circulating submicron-sized membranous vesicles released by endothelium have a 
major biological role in the vascular injury; EMPs have been shown to act as primary and secondary 
messengers of vascular inflammation, thrombosis, vasomotor response, angiogenesis, and 
endothelial survival. 
Phosphate is the major contributor to the level and biological activity of Calciprotein particles 
(CPPs) which are a new biological marker of CKD-MBD. Reports have shown that phosphate alone 
is not able to induce VSMCs mineralization, describing a synergistic action of both Ca and P in 
accelerated mineralization in vitro [16]. Insoluble CaP crystals generate when the concentration of 
calcium and phosphate exceeds the solubility limit. They can grow over time and finally precipitate 
as hydroxyapatite. The hepatic plasma protein fetuin-A (a natural calcification inhibitor) stabilizes 
colloidal protein–mineral complexes in the form of CPPs and mediates their clearance from the 
circulation. Primary CPPs, further, undergo topological rearrangement to find a more stable structure 
introduced as secondary CPPs [44]. The formation of CPP can be considered as a defense mechanism 
that prevents blood vessels from being occluded with insoluble CaP precipitates. The CPP level 
increases in the early stages of CKD, just before the rise of FGF23 and there are clinical findings that 
raise the hypothesis that CPPs might induce FGF23 [44,45]. In CKD patients, secondary CPPs have 
lower levels of calcification inhibitors including fetuin-A, and Gla-rich protein, readily taken up by 
the VSMCs inducing vascular calcification. While phosphate seems to be the driving force of CPP 
formation, his partner calcium seems to be a promoter of the inflammation-associated tissue damage 
forming a circle where increased mineralization triggers inflammation and vice-versa [44]. Recent 
studies have figured out the physiological and pathological significance of CPPs, its contributions to 
bone and mineral metabolism, and its role in tissue and organ impairments especially in 
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cardiovascular damage and inflammatory responses [16,46,47] (Figure 1). Based on these findings 
secondary CPPs could be a new biomarker for the pathological condition of CKD-MBD [47]. More 
studies are required to further clarify the role of CPPs as an essential mediator of CV damage and as 
a potential therapeutic target in CKD patients [47]. Recently, Ciceri et al. reported that ferric citrate 
prevents high Pi-induced calcium deposition by preventing apoptosis. Apoptosis has been proposed 
to be one of the mechanisms that initiate the calcification process by forming a nidus for the 
deposition of calcium and Pi crystals. Even in the status where VSMCs are already transformed with 
a procalcified stimulus being present, reverting apoptosis and inducing autophagy presumably 
contribute to stopping calcium deposition [48].  
  
Figure 1. Role of Calciprotein particles in cardiovascular disease. In chronic kidney disease (CKD) 
patients, secondary Calciprotein particles (CPPs) have lower levels of calcification inhibitors 
including fetuin-A and were readily taken up by the vascular smooth muscle cells (VSMCs) inducing 
vascular calcification. Phosphate seems to be the driving force of CPP formation. Figure 1 shows the 
significance of CPPs, its contributions to bone and mineral metabolism, in an inflammatory response, 
and its role in the cardiovascular damage.  
Animal experimental data suggest that higher dietary phosphate engages multiple mechanisms 
involved in hypertension, including overactivation of the sympathetic nervous system, increased 
vascular stiffness, impaired endothelium-dependent vasodilation, together with an increased renal 
sodium absorption or renal injury [49].  
On the other hand, there is limited evidence of a hyperphosphatemia-induced direct effect on 
cardiomyocytes. Dietary phosphate intake and hyperphosphatemia were frequently associated with 
abnormalities of the postcoronary arterial vessels in the myocardium and to interstitial fibrosis where 
hyperphosphatemia accelerate cardiac fibrosis as well as microvascular disease in experimental 
uremia [9,50]. In vitro studies showed that high Pi alone may not be able to generate cardiac 
hypertrophy but can initiate fibrosis [51]. Fibrosis, arising from non-myocytes and enhanced by 
cardiac myocytes, can promote increased wall stiffness and diastolic dysfunction. Moreover, fibrosis 
interrupts electrical signals, causing the tissue to be more arrhythmogenic [9,23]. Cardio markers and 
parameters of myocardial function, including Cardiac troponin T (cTnT), left ventricular max index 
(LVMi), left atrial dimensions (LAD), left ventricular end-systolic dimension (LVDs), left ventricular 
end-diastolic dimension (LVDd), interventricular septal thickness (IVST), and left ventricular 
posterior wall thickness (LVPWT), were reported consistently higher in a group of patients with 
higher serum phosphate (HSP) levels compared to those in the normal serum phosphate group (NSP) 
group, while left ventricular ejection fraction (LVEF) showed the opposite trend in a CKD cross-
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sectional study [52]. Furthermore, the lack of difference in mean arterial pressure (MAP) between the 
two groups suggested that cardiac remodeling including LVH and the declining LVEF might be 
associated with serum phosphate rather than hypertension and possibly this happens through 
triggering apoptosis of human cardiomyocytes.  
With respect to CV mortality, it is reported that risk assessment varied from 1.09–1.13 for 
phosphorus (every 1 mg/dL increase) to 1.13–1.28 for calcium (every 1 mg/dL increase) [53]. 
In conclusion, enhanced phosphate has detrimental effects on the cardiovascular system 
seriously affecting patient outcomes (brief summary presented in Figure 2). Phosphate is toxic, 
impairs endothelial cells, promotes the formation of CPPs, induces VSMC transformation to 
osteogenic phenotype, and initiates cardiac fibrosis that leads to cardiac remodeling. 
 
Figure 2. Pathophysiology of phosphate toxicity in the cardiovascular system. In CKD, higher serum 
phosphate levels are consistently linked with clinical and subclinical cardiovascular disease. 
Abbreviations: CPPs—Calciprotein particles; EMPs—endothelial microparticles; LVH—left 
ventricular hypertrophy; CHF—chronic heart failure; VSMCs—vascular smooth muscle cells; ↑ 
elevate; ↓ decrease. 
1.3. Role of Parathyroid Hormone 
Secondary hyperparathyroidism is a frequent complication of CKD characterized by an increase 
in PTH synthesis and secretion and by parathyroid gland hyperplasia. High levels of PTH have an 
impact on the cardiovascular system apart from the regulation of calcium and phosphate homeostasis 
[54]. Elevated PTH levels are a common finding in uremic patients which appears much earlier than 
hyperphosphatemia. PTH and FGF23 have both phosphaturic effects. The difference remains that 
only PTH has an impact on increased serum calcium. While PTH receptor (PTH1R), is present in bone 
and kidney, the klotho coreceptor is only expressed in the kidney [7,31]. In addition, PTH stimulates 
calcitriol synthesis that further contributes to increased serum calcium, whereas FGF23 has an 
opposite effect on vitamin D and calcium. In the physiologic state, FGF23 acts on the parathyroid 
gland by reducing gene expression and secretion while in the absence of Klotho, the parathyroid 
gland shows resistance to FGF23, so enhances PTH secretion. 
Experimental data have shown that PTH may directly affect the myocardium although the effect 
of PTH on the CV system is still under study.  
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PTH was shown to affect directly rat myocardial cells causing early death of cells by increasing 
calcium entry into the heart cells [55]. Calcium ions are crucial to myocardial excitation–contraction 
coupling and cardiac contraction and relaxation [56]. 
There are early reports by Amman et al. regarding the non-hemodynamic effect of PTH on 
cardiac fibrosis which was related to diastolic LV function [9]. An experimental rat model of CKD 
(5/6 nephrectomy) reported that continuous infusion of supraphysiological rates of synthetic PTH in 
animals with parathyroidectomy was associated with an extensive progression of VC—
independently of serum Pi levels or the presence of uremia [57]. Moreover, the higher PTH levels 
have direct trophic effects on cardiomyocytes, interstitial fibroblasts, and smooth muscle cells of 
intramyocardial arterioles, promoting cardiac hypertrophy and fibrosis. PTH activates fibroblasts 
and regulates pro-fibrotic factors, such as aldosterone and angiotensin II (PTH stimulates aldosterone 
secretion by increasing the calcium concentration in the cells of the adrenal zona glomerulosa directly 
by binding to the PTH/PTH-rP receptor and indirectly by potentiating angiotensin 2 induced effects) 
[54,58]. Additionally, PTH potentially would activate protein kinase C, which further on activates 
other proteins, such as TGF-b, that in turn, promote the proliferation of fibroblasts, collagen synthesis, 
and fibrosis [59,60]. In vitro studies have found that PTH shows to have chronotropic, inotropic, as 
well as hypertrophic effects on cardiomyocytes [55] and based on research it was represented that 
there is a source for a direct role of PTH on cardiac electrophysiology outside of its effect on serum 
calcium [61]. 
Furthermore, ex-vivo experiments have shown the interaction between PTH and 
norepinephrine release in isolated human atria and renal cortex tissue through activation of the 
PTH1-receptor subtype. This effect would be an explanation for another potential underlying 
mechanism of the sympathetic overactivity and the associated cardiovascular mortality seen in 
patients with ESRD [62]. 
In hemodialysis patients, like in the rat model, the effect of PTH on the myocardium and cardiac 
fibrosis was well perceived. The hormone was shown to raise the beating rate of myocardial cells and 
induced their death after prolonged hormonal exposure; PTH stimulates the cyclic AMP production 
and impairs energy production, transfer, and utilization by myocardial cells [63] and myofibrillar 
activity of creatine kinase [64]. The presence of sHPTH has also been shown to correlate with 
enhanced myocardial calcium content and impaired ventricular systolic and diastolic function [65].  
Despite a theoretical inverse association between plasma PTH concentration and left ventricular 
function, parathyroidectomy is not consistently associated with improvement in cardiac contractile 
function [66]. This suggests that changes induced by PTH could be irreversible in the case of long-
standing severe hyperparathyroidism, or other factors contributing to myocardial dysfunction were 
more important than PTH excess or PTH interferes with the other risk factors of CVD. Despite a 
theoretical inverse relation between plasma PTH concentration and left ventricular function, 
parathyroidectomy is not consistently associated with improvement in cardiac contractile function 
[66]. This suggests in the case of long-standing severe hyperparathyroidism changes induced by PTH 
could be irreversible, or other factors with an impact on myocardial dysfunction are more important 
than PTH excess or PTH interferes with the other risk factors of CVD. Furthermore, the inconclusive 
results of the EVOLVE trial have been linked with this uncertainty since in intent-to-treat analysis a 
significant advantage of cinacalcet treatment over best presently available standard treatment in the 
combined primary endpoint (cardiovascular events plus death) was not shown, despite a marked 
decrease in serum PTH [67]. However, in the subanalysis, when it was adjusted for major 
confounders such as age and study drug discontinuation, the better control of hyperparathyroidism 
correlated with a significant advantage in hard outcomes. It was reported that PTH increases with 
age, weight, BMI, SBP, and LDL, all risk factors for CVD. Increased SBP would be a hemodynamic 
effect of PTH on cardiac remodeling [68,69]. Evidence suggests that PTH has vascular effects [68]. 
Here its potential effects on endothelial dysfunction, and increased serum levels of endothelin-1 and 
IL-6 could be mentioned. In addition, PTH may stimulate the vascular smooth muscle cells to produce 
factors including collagen and beta-1 integrin which could, in turn, remodel the peripheral 
vasculature. Another potential effect of PTH would be the increase of renin release and activation of 
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the renin–angiotensin system, a process mediated by serum calcium and renal 1-alpha hydroxylase 
[69]. Aman et al. have underlined the effect of PTH as the major determining factor of coronary artery 
lesions, ranging from the discontinuity of the elastic lamina to the calcification of the medial layer, 
confirming the agreeable action of PTH [70]. 
In conclusion, there are clinical and experimental reports which support the hypothesis that PTH 
behaves as a systemic uremic toxin, with direct and indirect effects on uremic cardiomyopathy. PTH 
acts through four major cardiovascular effects; contractile disturbance, cardiomyocyte hypertrophy, 
cardiac interstitial fibrotic, and vasodilator effect. Severe sHPTH is an important threat to CKD 
patient outcomes affecting CV morbidity and mortality and remains an important therapeutic target 
to prevent bone and CV complications in such patients. 
1.4. Role of Vitamin D 
During the last decades, the role of Vit D on CV events has triggered a lot of studies where 
observational studies (OS) have reported an association of vitamin D deficiency with cardiovascular 
disease, including carotid intima-media thickness, peripheral vascular disease, and cardiovascular 
death. Vitamin D supplementation diminishes levels of inflammatory markers and lipids 
(particularly triglycerides), improves endothelial function (as measured by brachial artery flow-
mediated dilatation) and blood pressure (BP) control in the general population with or without 
vitamin D deficiency [71]. Besides, nephrologists have supported supplementation with 1,25-
dihydroxy vitamin D in patients with ESRD since the inactivation of Vit D with the progression of 
CKD was known. If not managed on time, 1,25(OH)2D deficiency might promote the classic view of 
mineral and bone disorders (MBDs) such as secondary hyperparathyroidism and osteitis fibrosa 
cystica. These abnormalities together with endothelial dysfunction and vascular changes from the 
early stages of CKD [72], results in further vascular calcification and arterial stiffness [73]. Vitamin D 
has been shown to have anti-inflammatory and anti-oxidative properties and additionally 
downregulates the expression of renin, correlating with an increased prevalence of hypertension, 
heart failure, CV events, and a higher CV mortality rate in CKD [74–76].  
In vitro data have shown a direct effect of vitamin D on endothelial function, related to decreased 
oxidative stress and increased levels of endothelial nitric oxide synthase (eNOS). These findings are 
supported by the promising results of a few randomized clinical trials which represented beneficial 
effects of nutritional vitamin D supplementation or paracalcitriol on endothelial function (brachial 
artery flow-mediated dilatation) in CKD stage 3–4 [77,78]. Other positive effects on Vit D 
supplementation were noticed on inflammation markers, intracellular cell adhesion molecule, 
vascular cell adhesion molecule, E-selectin parathyroid hormone, and arterial stiffness [79]. 
A recent meta-analysis supports the positive effect of vitamin D intervention on endothelial 
function mainly in younger patients, apparently due to an earlier diagnosis, where vascular 
remodeling has not yet been established. Limitations of this meta-analysis were the small number of 
studies included, and the short duration of intervention suggesting a need for larger and longer 
studies on this topic, with sufficient power to assess hard endpoints [80]. The controversies remain 
also on the impact of Vitamin D on cardiac structure and function. 
Experimental studies through a specially engineered mouse model have shown that targeted 
deletion of the vitamin D receptor gene increased cardiomyocyte size and LV weight without fibrosis 
[81]. Similarly, an association between vitamin D deficiency and increased myocardial collagen 
content, impairment of cardiac contractile function, and increased cardiac mass was reported 
previously [82,83]. On the other hand, beneficial effect of treatment with activated vitamin D on 
attenuation of myocardial hypertrophy [84] and prevention of heart failure [85] in experimental 
models were not supported neither by Primo and Opera trials, which showed that 48 or 52 weeks of 
treatment with paricalcitol, respectively, at a dose that adequately controls secondary 
hyperparathyroidism did not regress LV hypertrophy or improve LV systolic and diastolic 
dysfunction in CKD stage 3–5. Moreover, the promising effect of lowering CV-related 
hospitalizations needs further confirmation [86,87].  
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In addition, based on the data of the recent meta-analysis including 38 studies involving 223, 429 
patients (17 RCTs, n = 1819 and 21 OSs, n = 221,610) it could be concluded that that the existing RCTs 
that used the intention-to-treat principle do not provide an adequate or conclusive evidence that Vit 
D supplementation affects the mortality of patients with CKD while in observational studies Vit D 
treatment was significantly correlated with a 38% reduction in all-cause mortality and 45% reduction 
in CV mortality. The different findings between the RCTs and OSs demonstrate that confidence on 
neither should be absolute and the conclusion was that large-size RCTs with a proper dose and 
sufficient treatment time, in the true vitamin D-deficient patients with CKD are needed in the future 
to assess, prospectively, any potential differences in survival [88]. 
2. Importance of New CKD-MBD Biomarkers in Early Cardiovascular Risk Assessment 
Considering significant CV risk and mortality in patients with CKD, there is a growing attempt 
to find a reliable biomarker that would timely detect not only kidney disease but also define patients 
under higher risk to reduce CV mortality. 
Compared to the “older” CKD-MBD biomarkers and already established in clinical routine, 
phosphate and PTH, which however display increased levels when CKD is already advanced, newer 
biomarkers, FGF23, Klotho, and sclerostin, give a bit more hope as there is growing evidence 
suggesting that their disturbed serum levels can detect initial CKD (Table 1). 
Table 1. The importance of the FGF-23–klotho–sclerostin axis in left ventricular hypertrophy in CKD. 
FGF-23–
Klotho–
Sclerostin 
Axis 
Cellular Level Tissue Level Circulation 
Clinical 
Observation 
Therapeutic 
Potential 
FGF-23 
FGF23 directly induces 
LVH by binding to the 
FGFR-4 in 
cardiomyocytes 
 
RAAS activation 
induces FGF23 
expression in cardiac 
myocytes and 
stimulates pro-fibrotic 
crosstalk between 
cardiac myocytes and 
fibroblasts 
FGF23 increases 
production of TGF-
β, lipocalin-2, and 
TNF-α, and thus 
promoting the 
inflammation 
process 
 
LVH is shown to be 
associated with an 
increase in both 
myocardial and 
serum intact FGF23 
 
FGF23 contributes 
to renal anemia 
development -> 
contribution to 
LVH aggravation  
FGF23 levels 
correlate positively 
with LVH and 
negatively to left 
ventricular ejection 
fraction in patients 
on hemodialysis 
Vitamin D treatment 
reduces LVH 
 
Ferric citrate lowers 
FGF23 levels and 
improves cardiac 
function and patient 
survival 
Klotho 
Cardioprotective effect 
by downregulation of 
TRPC6 channels in 
cardiomyocytes, 
important for 
angiotensin II-induced 
hypertrophy signaling 
Klotho upregulation 
inhibits TGF-β1-
induced fibrosis and 
pathogenic Wnt/ β-
catenin signaling in 
cardiomyocytes 
Cardiomyocytes and 
cardiac fibroblasts 
express klotho 
Uremic serum or 
TGF-β1 suppressed 
klotho expression 
by cardiomyocytes  
FGF23/klotho ratio 
correlates with 
changes in left 
ventricular mass 
 
Low klotho levels 
are associated with 
CV events 
 
Serum klotho is an 
independent 
biomarker of a left 
ventricular mass 
index 
Klotho 
administration 
attenuates high-
phosphate induced 
renal and cardiac 
fibrosis and 
improved both renal 
and cardiac function 
Sclerostin 
Lacking data about the 
association with LVH 
Lacking data Lacking data 
Elevated serum 
sclerostin levels in 
patients with aortic 
valve calcification 
with increased 
upregulation of 
sclerostin mRNA 
Not yet clear 
whether therapeutic 
decrease of 
sclerostin levels is 
beneficial or 
deleterious for CV 
outcome 
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Abbreviations: LVH—left ventricular hypertrophy; RAAS—renin–angiotensin–aldosterone system; 
TRPC6—transient receptor potential canonical type 6; TGF-β—transforming growth factor β; TNF-
α—tumor necrosis factor α. 
2.1. Role of FGF23  
FGF23, a 32 kDa glycoprotein, has been defined as a phosphaturic hormone produced by 
osteocytes and osteoblasts [89]. In the physiological state, its main role is to maintain normal 
phosphate levels in the blood through downregulation of sodium-phosphate (NaPi) cotransporters 
in kidney proximal tubule and, thus, reducing the phosphate reabsorption in the kidney [89]. In 
addition, FGF23 downregulates 1-α-hydroxylase in proximal tubules, the enzyme responsible for 
converting 25-OH-vitamin D into his active form, 1,25(OH)2-vitamin D [89]. In this way, FGF23 
regulates phosphate levels both directly, through NaPi cotransporters, and indirectly, through 
vitamin D metabolism and phosphate absorption in the gut. 
FGF23 acts by binding with the transmembrane protein, α-klotho, which is expressed mainly in 
kidney proximal and distal convoluted tubule, parathyroid and pituitary glands, but also in other 
organs [90,91]. As FGF23 suppresses α-klotho expression in the kidney, it may decrease levels of 
secreted klotho in the circulation [90,92]. 
Studies performed so far confirmed that patients with CKD have increased FGF23 levels even 
from the early stages of the disease [93,94]. As high mortality in CKD patients is well known, the role 
of FGF23 in CV mortality was intensively investigated, both in experimental and clinical settings. A 
recent meta-analysis concluded that elevated FGF23 levels are positively associated with CV events 
and all-cause mortality in HD patients [95]. Data on repeated measurements of FGF23 levels in 
patients with CKD may identify subpopulation of patients that have higher mortality risk, as it was 
shown that those patients with slower rise in FGF23 levels in the course of five years have five times 
higher risk of death and those with rapid rise in FGF23 levels have 15 times higher risk of death 
compared to the patients with stabile FGF23 levels [96]. These data indicate that FGF23 acts as a toxin 
in developed CKD-MBD. Most of the studies investigating the association of FGF23 and mortality in 
CKD patients analyzed the presence of cardiac hypertrophy, known to be very common in CKD, and 
activation of the renin–angiotensin–aldosterone (RAAS) system. In patients with diabetic 
nephropathy and early CKD (stages 2 and 3), lower plasmatic Klotho and higher FGF23 levels were 
associated with a higher risk of concentric hypertrophy, and, thus, higher cardiovascular 
hospitalization [97]. It was shown that FGF23 stimulates the renin–angiotensin system by 
suppressing the expression of angiotensin-converting enzyme-2 (ACE2) in the kidney [98]. The study, 
which included both in vitro investigation of cardiac fibroblasts and myocytes and myocardial 
autopsy samples of patients with end-stage CKD, demonstrated that RAAS activation is responsible 
for the induction of FGF23 expression in cardiac myocytes and stimulation of pro-fibrotic crosstalk 
between cardiac myocytes and fibroblasts [99]. Besides, FGF23 also increases the production of 
transforming growth factor-β (TGF-β), lipocalin-2, and tumor necrosis factor-α (TNF-α), which are 
well known inflammatory markers [98].  
Anemia is an important CKD complication that contributes to higher CV risk and mortality. It 
is important to underline that FGF23 also contributes to renal anemia development and inhibition of 
FGF23 signaling may decrease erythroid cell apoptosis, attenuate inflammation, and result in 
increased serum iron and ferritin levels [100]. Hence, it may be concluded that FGF23 increases CV 
risk either directly (by action on heart) and/or indirectly (RAAS activation, contribution to renal 
anemia, and inflammation), and also stimulates other pathophysiological factors that contribute to 
further disease progression. Regarding the relation to LVH, experimental data indicate that FGF23 
can exert its action even if α-klotho is not present and to induce hypertrophy of cardiac myocytes 
[101]. Indeed, it has been shown that FGF23 directly induces LVH by activation of fibroblast growth 
factor receptor-4 (FGFR-4) in the absence of membrane α-klotho and that administration of soluble 
klotho attenuates hypertrophy in mice [102]. LVH, on the other hand, is shown to be associated with 
an increase in both myocardial and serum intact FGF23 [103].  
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Clinical data suggest the association of FGF23 levels and increased CV risk throughout the CKD 
stages. FGF23 is shown to be associated with increased risk of CV events and mortality in diabetic 
patients even with normal or mildly impaired kidney function [104]. Furthermore, FGF23 levels 
correlated positively with LVH and negatively to left ventricular ejection fraction in patients on 
hemodialysis, in whom FGF23 was shown to be an independent predictor of overall mortality [105].  
Some authors pointed that predictive potential of FGF23 of CV mortality is more emphasized in 
patients in intermediate eGFR tercile (with mean value of 60 mL/min) [106]. 
These clinical data strongly support the role of FGF23 as direct cardiac toxin, which causes 
hypertrophy of cardiomyocytes that are exposed to less blood supply in the further course of the 
disease. Apart from the association with CV risk and mortality, the relationship of FGF23 with overall 
mortality can be explained through the stimulation of other pathways (inflammation for instance) 
that lead to CKD progression and mortality.  
Experimental data, on the other hand, indicate that the progression of LVH in CKD could be 
ameliorated. It is important to note that specific blockade of FGFR4, as shown in 5/6 nephrectomy rat 
model, attenuates LVH [107]. Moreover, experimental data in uremic rats indicated that vitamin D 
treatment reduced LVH, FGFR-4 expression, and calcineurin/nuclear factor of activated T cells 
(NFAT) signaling activation, and, therefore, showing calcitriol cardioprotective effects [108]. 
Encouraging experimental data also indicate that early administration of ferric citrate slows CKD 
progression, lowers FGF23 levels, and improves cardiac function and survival [109]. Hence, LVH can 
be treated in CKD and CV risk can be reduced, either by lowering FGF23 levels or by inhibiting its 
effect on the FGFR-4. To conclude, FGF23 acts as a toxin in CKD and has an important role in CKD-
MBD development and, most importantly, is associated with increased CV risk in CKD patients. 
Therapeutic strategies to lower FGF23 serum levels and/or to inhibit its action on FGFR-4 might be 
beneficial for the CV and overall outcome improvement. 
Early diagnosis of CKD-MBD is an appropriate time for prevention of CKD complications and 
reduction of CV risk. Monitoring FGF-23 levels could detect patients with higher CV risk and 
suggests more regular visits at nephrology departments. 
2.2. Role of Klotho 
In close relation to FGF23 levels elevation, it is known that patients with CKD are in klotho-
deficiency, which, according to the existing knowledge, contributes to high CV mortality among CKD 
patients. Decreased soluble klotho levels in the circulation could be detected very early in CKD, from 
stage 2, and in urine even from CKD stage 1 [110]. 
On the cellular level, it has been shown that circulating klotho has a cardioprotective effect by 
downregulation of TRPC6 channels in heart as an antagonist of the Wnt/b-catenin pathway [111]. 
Klotho-deficient CKD mice had more pronounced cardiac hypertrophy than wild-type CKD mice 
and even after normalization of serum phosphate and FGF23 levels, cardiac hypertrophy was not 
improved, meaning that klotho-deficiency is an important cause of cardiac hypertrophy in CKD, 
independently of FGF23 and phosphate [112]. Klotho deficiency in CKD results not only in cardiac 
hypertrophy but is involved in cardiac fibrosis development. It has been shown that endogenous 
klotho is expressed both by human cardiomyocytes (HCMs) and cardiac fibroblasts (HCFs) and that 
uremic serum or TGF-β1 suppressed klotho expression by HCMs [113]. Klotho upregulation inhibits 
TGF-β1-induced fibrosis and pathogenic Wnt/ β-catenin signaling in HCMs [113]. 
Clinical studies also support the cardioprotective role of klotho. In patients with CKD 3 stage, a 
change in FGF23/klotho ratio correlated with the changes in left ventricular mass [114]. In 
hemodialysis patients, low klotho levels were associated with CV events, independently from other 
CKD-MBD factors [115]. Analysis of the LURIC (Ludwigshafen Risk and Cardiovascular Health) 
study did not show any additional predictive power of CV and mortality risk in patients with normal 
kidney function [116]. On the contrary, in patients with CKD, as presented by the KNOW-CKD study, 
serum klotho was shown to be an independent biomarker of a left ventricular mass index, but not of 
arterial stiffness [117].  
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Klotho deficiency also contributes indirectly to increased CV risk in CKD. Known to be 
expressed in the vasculature, klotho deficiency is involved in VC and endothelial dysfunction 
development [118] and, therefore, contributes to increased arterial stiffness and pressure overload.  
Experimental data indicate that calcified human aortic valves have lower klotho levels and that 
treatment with recombinant klotho reduces high phosphate-induced osteogenic activity in human 
aortic valve interstitial cells [119]. Another study confirmed that klotho administration attenuated 
high-phosphate induced renal and cardiac fibrosis and improved both renal and cardiac function in 
the absence of previous kidney disease [120]. Taken together, experimental data encourage that 
treatment of klotho deficiency in CKD may have a beneficial effect on heart disease in CKD.  
Whereas klotho did not predict CV events (death, atherosclerotic events, and decompensated 
heart failure) in patients CKD stages 2–4, FGF23, on the other hand, was significantly associated with 
future decompensated heart failure [121].  
Bearing in mind klotho/FGF23 axis disturbance, the klotho deficiency, and high FGF23 levels, in 
patients with CKD, it has been suggested that the klotho/FGF23 axis could be not only diagnostic and 
prognostic biomarkers of CKD and CV disease but could be treatment targets as they contribute to 
the CKD progression and development of CV disease as complication [122]. 
2.3. Role of Sclerostin  
Sclerostin, a protein produced by osteocytes, and coded by the SOST gene on chromosome 
17q12-q21, is an inhibitor of wingless-type mouse mammary tumor virus integration site (Wnt) 
pathway in osteoblasts, which is responsible for osteoblastogenesis [123]. In this way, sclerostin 
inhibits bone formation in a healthy state. Although previously described to be secreted as 27 kDa 
monomer only by osteocytes [124,125], later research pointed to the secretion also by other cells 
(osteoblasts, osteoclasts, chondrocytes, cementocytes) [126,127]. Interestingly, the SOST gene is found 
to be also expressed in other tissues and organs and, besides bone, primarily in heart, lung, aorta, 
and kidney [128,129]. Based on these data, sclerostin was no longer considered to be a bone-specific 
protein and marker of bone turnover, but the topic of further research aiming to understand its role 
in extraosseal tissues and organs. Unfortunately, the exact nature of sclerostin in those are not fully 
understood, neither in health, nor in a disease. Some of the limiting factors are the weak association 
between protein expression in the tissue and mRNA levels and different nature of sclerostin in 
different parts of the same tissue [130].  
Clinical data on the association of sclerostin with CV risk and mortality are not very clear. It is 
known that patients with CKD have increased serum sclerostin levels already from the initial stages 
[131]. As the SOST gene is present in the heart and vascular tissue, the potential association of serum 
sclerostin with increased CV risk in CKD patients has also been investigated and is still an important 
topic in experimental and clinical research. However, compared to the studies investigating the 
association of FGF23 and klotho with LVH, most studies linked sclerostin with the presence of 
atherosclerosis and VC in CKD. Studies investigating the heart in CKD referred to the relationship 
between sclerostin and valvular calcification. In addition, sclerostin may exert an indirect effect on 
heart disease in CKD, by taking part in VC development and, hence, through increased peripheral 
vascular resistance and heart failure.  
Elevated serum sclerostin levels were seen in patients with aortic valve calcification with 
increased upregulation of sclerostin mRNA [132]. Sclerostin is shown to be an independent risk factor 
for heart valve calcification in patients with CKD stages 3–5 and is increased in serum before the 
increase in serum phosphate and PTH is seen [133]. In addition, in patients with CKD stages 2–5, 
serum sclerostin was reported to be associated with inflammation markers, phosphate, FGF23, 
indoxylsulphate and p-cresyl sulphate, β2-microglobulin, and arterial stiffness [134], emphasizing its 
role in CKD-MBD development. 
High sclerostin serum levels (>200 pg/mL) were reported to be associated with increased carotid-
femoral pulse wave velocity (>9.5 m/s) in HD patients [135]. Although during 2-year follow-up HD 
patients who died had higher sclerostin levels, sclerostin did not predict survival [136]. Similarly, to 
Toxins 2020, 12, 140 13 of 23 
 
this study, it was reported that higher CV risk in HD patients was associated with sclerostin values 
above the median (>84pmol/L) during the five-year follow up period [137].  
Recent experimental data suggest a positive correlation between the presence of VC in CKD rats 
and vascular Wnt3a and β-catenin expression together with blood pressure variability, but no 
association with sclerostin was seen [138]. In CKD patients, sclerostin was positively associated with 
VC (coronary arteries and thoracic aorta, but not with those at the aortic or mitral valves and it did 
not predict cardiovascular events) [139]. Meta-analysis performed by Kanbay et al. showed that 
serum sclerostin was not associated with all-cause and CV mortality [140]. Previously, it has been 
shown that serum sclerostin values were associated with fatal and nonfatal CV events in non-dialysis 
CKD patients [141]. On the other hand, the NECOSAD study indicated that incident dialysis patients 
with higher sclerostin level had better CV survival [142].  
Up to now, there are some data suggesting the association of serum sclerostin with vascular and 
valvular calcification in CKD patients and the number of studies is very scarce with conflicting 
results. On the other hand, data on the potential relationship of sclerostin with uremic 
cardiomyopathy are lacking. Taken together, clinical studies on the role of sclerostin in CKD report 
inconclusive data and the exact role of sclerostin in CKD-MBD and CV risk is yet not clear with a 
need for further investigation.  
At present, it cannot be clearly stated whether serum sclerostin turns into a toxin in CKD and 
increases CV risk and mortality, or if it is only a marker of disturbed bone and (cardio)vascular and 
valvular metabolism. The critical point here is the ability to confirm the origin of high serum 
sclerostin levels and then to explain the reason for such increased values. Similarly, CKD-MBD 
treatment for reducing sclerostin levels is a double-edged sword. Although it has been shown that 
the application of anti-sclerostin antibodies improves bone and mineral density and reduces fracture 
risk in osteoporosis [143], there is also important data indicating that such treatment can increase CV 
risk in patients with primary osteoporosis [144].  
Nevertheless, new studies on this topic should reveal the real physiological and 
pathophysiological roles of sclerostin in heart and vascular disease in patients with CKD and will 
direct future therapeutic strategies. 
2.4. Role of OPG-RANK-RANKL System in CKD-MBD 
Bone disease is an important component of CKD-MBD, that is linked to vascular disease and 
described as a calcification paradox [145] (depicted in Figure 3). 
The disturbed OPG-RANK-RANKL pathway might be one of the contributors to bone disease 
and VC development in CKD. In physiological conditions, osteoprotegerin (OPG) is a protein which 
inhibits activation and differentiation of osteoclasts by blocking the binding of receptor activator of 
nuclear factor kappa–B ligand (RANKL) to RANK expressed on osteoclast precursors [145]. It has 
been shown that osteoprotegerin is produced by the arterial wall and other tissues [146].  
Experimental data indicate that OPG knockout in mice is responsible for osteoporosis and VC 
development [147]. Moreover, OPG knockout mice displays higher RANKL and RANK levels, as 
well as OPG downregulation detected in calcified human arteries [148,149]. An important mediator 
of the opposite OPG-RANK-RANKL system regulation in bone and vasculature might be TGF-β, as 
it increases the OPG/RANKL ratio in bone and decreases in vasculature, disabling the VC inhibition 
by OPG [145]. Clinical data showed that coronary artery calcification score correlated positively with 
serum osteoprotegerin and negatively with RANKL, and serum osteoprotegerin correlated positively 
with the progression of coronary artery calcification score in hemodialysis patients [150].  
Nevertheless, the calcification paradox seems to be very complex and most likely disturbs 
several pathways deserving more detailed experimental and clinical explanation. 
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Figure 3. Mechanism of increased mortality in patients with chronic kidney disease. ↑ 
increases/increased; ↓ decreases/decreased. 
3. Conclusion 
Although the management of CKD patients was significantly improved, we are still faced with 
a high rate of CV mortality. In this review, we tried to go from each of the candidate mineral disorder 
to the CV abnormalities (summarized in Table 2). The risks of each mineral disorder from the oldest 
to the newest one varied with each kind of cardiac abnormality, which means that it is a significant 
challenge to prevent all cardiac abnormalities, even if CKD-MBD control has been guided in strict 
compliance with the guidelines. Therefore, we do have CKD-MBD markers acting as toxins: 
phosphate, PTH, and FGF23, as present important targets for treatment. On the other side, 
cardioprotective CKD-MBD markers such as vitamin D and klotho could be additional and very 
helpful points to treat. Finally, the newest CKD-MBD biomarker sclerostin, that interplays in CKD-
MBD developing pathways, is still debatable concerning its protective role or acting as a toxin and 
consequently increasing CV risk development. 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic kidney disease 
↑ FGF-23  
↓ Calcium 
↓ 1,25(OH) 
Vitamin D  
↑ Phosphate  
↑ Calcium-
phosphate 
product  
↑ PTH  ↓ Decreased bone 
and mineral 
density 
Soft-tissue 
calcification 
(valvular and 
vascular) 
↑ fracture risk  
↑ cardiovascular 
risk  
Left ventricular 
hypertrophy 
Malnutrition and 
inflammation 
Anemia  ↓ Klotho 
↑ cardiovascular 
and overall 
mortality 
↑ Calcium 
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Table 2. CKD-mineral and bone disorder (MBD) biomarkers, role in bone metabolism and the 
cardiovascular system. 
CKD-MBD 
Biomarkers 
Role in Bone Metabolism Vascular Calcification 
Uremic 
Cardiomyopathy 
Phosphate 
Major trigger in CKD-MBD 
↑P Ca↑→Vit D ↑ →PTH↑→  
↑P Ca ↓→Vit D↓→FGF23↑→  
Promotes VC 
Impairs endothelial function 
Cardiac fibrosis 
PTH 
Key mediator of bone turnover 
Regulates P and Ca homeostasis 
Complex paracrine and systemic effect 
Promotes VC 
Impairs endothelial function 
Cardiac 
electrophysiology 
Cardiomyocyte 
hypertrophy 
Cardiac interstitial 
fibrosis 
Vit D 
Key role in Ca, P homeostasis 
Depletion promote sHPTH and 
osteitis fibrosis cystica 
Biphasic curve of Vit D on calcification 
Increases collagen 
↓Vit D impair → s 
contractile function 
Increases cardiac 
mass 
Klotho 
Acts as a Wnt-inhibitor 
Modify bone metabolism 
Inhibitor of VC 
Klotho deficiency impair endothelial  →
function 
Klotho  
deficiency→ LVH 
Cardiac fibrosis 
FGF23 
Posphaturic hormone 
acts through α-klotho Is not clear if it has a direct effect on VC 
Concentric 
hypertrophy 
Sclerostin Inhibits bone turnover Marker of vascular calcification 
There are no 
conclusive data 
Abbreviations: VC—vascular calcification; P—Phosphate; LVH—left ventricular hypertrophy; 
sHPTH—secondary hyperparathyroidism. → - brings to; ↓ decrease;↑increase.  
Diagnosis of CKD-MBD in the early development of CKD (stages 1 and 2) would be of great 
importance in preventing CKD progression, its complications, and would improve patients’ survival 
and quality of life. 
Focusing on such toxins and/or their relevant mediators at early CKD stages might help to 
interfere over time with the vicious cycle of the cardio–renal connection, and improve the outcome 
of patients. Further clinical studies exploring the beneficial influence of therapy in CKD (vitamin D, 
iron replacement, anemia treatment, etc.) and the association to FGF-23 and sclerostin levels with the 
cardiovascular outcome, would be of great help in understanding the complex pathophysiological 
mechanism of CKD-MBD.  
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